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ABSTRACT: The X-ray crystal structure of arginase from Schistosoma mansoni
(SmARG) and the structures of its complexes with several amino acid inhibitors have
been determined at atomic resolution. SmARG is a binuclear manganese metal-
loenzyme that catalyzes the hydrolysis of L-arginine to form L-ornithine and urea, and
this enzyme is upregulated in all forms of the parasite that interact with the human host.
Current hypotheses suggest that parasitic arginases could play a role in host immune
evasion by depleting pools of substrate L-arginine that would otherwise be utilized for
NO biosynthesis and NO-dependent processes in the immune response. Although the
amino acid sequence of SmARG is only 42% identical with that of human arginase I,
residues important for substrate binding and catalysis are strictly conserved. In general,
classical amino acid inhibitors such as 2(S)-amino-6-boronohexanoic acid (ABH) tend
to bind more weakly to SmARG than to human arginase I despite identical inhibitor
binding modes in each enzyme active site. The identification of a patch on the enzyme
surface capable of accommodating the additional Cα substitutent of an α,α-
disubstituted amino acid inhibitor suggests that such inhibitors could exhibit higher affinity and biological activity. The
structures of SmARG complexed with two different α,α-disubstituted derivatives of ABH are presented and provide a proof of
concept for this approach in the enhancement of enzyme−inhibitor affinity.
Schistosomiasis, also known as bilharzia or snail fever, is aneglected tropical disease caused by parasitic schistosomes
(also known as blood flukes) indigenous to tropical and
subtropical regions of the developing world.1−4 Biomphalaria
freshwater snails serve as intermediate hosts for Schistosoma
mansoni and release infectious larvae (cercariae), which burrow
into human skin upon contact with contaminated water
sources. After definitive host penetration, the parasite trans-
forms into a schistosomulum that enters the circulation and
migrates to the hepatic portal and mesenteric veins surrounding
the liver. Here, schistosomula develop into sexually mature
adults (male and female forms) that can evade immunity and
thrive for many years.5−7 Intravascular adult females produce
hundreds of eggs daily during this time, which either cross the
intestinal lumen to continue the lifecycle or circulate to the liver
where they induce a robust host immunological response.5
Chronic inflammation of the liver ultimately results, leading to
portal vein hypertension and severe hepatic fibrosis. Although
schistosomiasis is usually treated effectively with praziquantel,
currently believed to target schistosomal voltage-gated Ca2+
channels,8 the continuous threat of praziquantel-resistant
schistosomes portends an urgent need for alternative drug
targets.9−12
The binuclear manganese metalloenzyme arginase may
comprise just such an alternative. Although arginase activity
was first discovered in S. mansoni 50 years ago13 and implicated
in L-proline biosynthesis,14 S. mansoni arginase (SmARG) was
not enzymatically characterized until recently.15 The full-length
mRNA for SmARG encodes a 364-residue protein with an
amino acid sequence that is 42 and 40% identical with those of
human arginases I and II, respectively, which catalyze the
hydrolysis of L-arginine to yield L-ornithine and urea (Figure
1a).16,17 All residues important for catalysis by the human
isozymes, including two histidine and four aspartate ligands to
the binuclear manganese cluster, are strictly conserved in
SmARG. Interestingly, SmARG exhibits a relatively high
turnover number of 537 s−1, approximately 2-fold higher than
that measured for human arginase II and 20% higher than that
reported for human arginase I.18,19 Using a homology model of
SmARG based on the crystal structure of human arginase I,16
Fitzpatrick and colleagues predicted the formation of a disulfide
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linkage between proximal residues C291 and C332 in the active
site; the enzyme activity is significantly reduced in the presence
of reducing agents, consistent with the potential functional
relevance of a disulfide linkage.15
SmARG is expressed in all life stages of the parasite that
interact with the human host15 and is hypothesized to play a
role in immune evasion. By depleting the L-arginine substrate
otherwise utilized for nitric oxide (NO) biosynthesis, SmARG
can attenuate the anti-schistosomula NO-mediated immune
response of classically activated macrophages.20 A similar
strategy of arginase-facilitated immune evasion is exploited by
Leishmania parasites in leishmaniasis,21−23 Helicobacter pylori in
peptic ulcer disease,24,25 and certain cancer tumor cells.26−29
Accordingly, inhibition of SmARG might render the parasite
more susceptible to the immune response. If so, then SmARG
may comprise a new target for structure-based drug design in
the treatment of schistosomiasis.15
As the first step in exploring the “druggability” of SmARG,
we now report the X-ray crystal structures of the unliganded
enzyme and its complexes with selected inhibitors (Figure 1b),
including the classical boronic acid amino acid inhibitors 2(S)-
amino-6-boronohexanoic acid (ABH)30 and S-(boronoethyl)-L-
cysteine (BEC).31 Additionally, we report crystal structures of
SmARG complexes with the N-hydroxyguanidinium amino
acids N-hydroxy-L-arginine (NOHA)32 and nor-N-hydroxy-L-
arginine (nor-NOHA),33 as well as the simple amino acids L-
ornithine (the catalytic product), L-lysine, and L-valine. Finally,
to advance beyond classical amino acid inhibitor designs, we
report the crystal structures of SmARG complexed with two
novel α,α-disubstituted amino acid derivatives of ABH: (R)-2-
amino-6-borono-2-[2-(piperidin-1-yl)ethyl]hexanoic acid
(ABHPE)
34 and (R) -2 -amino-6 -borono-2-[1 -(3 ,4 -
dichlorobenzyl)piperidin-4-yl]hexanoic acid (ABHDP).
35 The
additional α-substituents of ABHPE and ABHDP make new
interactions that enhance enzyme−inhibitor affinity. These
studies illuminate structure−function relationships relevant to
the understanding of catalysis by SmARG and provide a
foundation for exploring the design of next-generation
inhibitors targeting a distinctive new region of the protein
surface.
■ MATERIALS AND METHODS
Materials. Manganese(II) chloride tetrahydrate (≥99%), L-
arginine, and α-isonitrosopropiophenone were purchased from
Sigma. Tris(2-carboxyethyl)phosphine hydrochloride (98%,
TCEP) was purchased from Gold Biotechnology. ABH was
purchased from Enzo Life Sciences (Farmingdale, NY).
NOHA, nor-NOHA, and BEC were purchased from Cayman
Chemical Co. (Ann Arbor, MI). ABHPE and ABHDP were the
generous gifts of New England Discovery Partners. A 30% (w/
v) PEG 20000 solution, a 50% (w/v) PEG 3350 solution, a
50% (w/v) PEG 10000 solution, and a 100% Tacsimate (pH
7.0) solution were purchased from Hampton Research. All
other chemicals were purchased from Fisher Scientific.
Expression and Purification of SmARG. A silent
mutation was introduced into the gene encoding wild-type
SmARG prepared in a TOPO vector to eliminate a native NdeI
site by using the QuickChange method (Stratagene) with the
following oligonucleotide primers [sense, 5′-GGT AAT ATG
AGT CGG GCG GCA CAC ATG CAG CAG ACA AAA CAA
TAA TCG-3′; antisense, 5′-CGA TTA TTG TTT TGT CTG
CAT GTG TGC CGC CCG ACT CAT AAT ACC-3′
(underlined bases indicate the silent mutation)]. The coding
sequence for SmARG was then amplified by polymerase chain
reaction (PCR) using oligonucleotide primers [sense, 5′-GCA
GCA CAT ATG ATG TTG AAA TCA GTC GCG ACC-3′;
antisense, 5′-GCA GCA CTC GAG TTA TTG TTT TGT
CTG CAT GTG TGC-3′ (underlined bases represent the
Figure 1. (a) Reaction catalyzed by arginase. (b) Arginase inhibitors 2(S)-amino-6-boronohexanoic acid (ABH), S-(boronoethyl)-L-cysteine (BEC),
N-hydroxy-L-arginine (NOHA), nor-N-hydroxy-L-arginine (nor-NOHA), (R)-2-amino-6-borono-2-[2-(piperidin-1-yl)ethyl]hexanoic acid (ABHPE),
and (R)-2-amino-6-borono-2-[1-(3,4-dichlorobenzyl)piperidin-4-yl]hexanoic acid (ABHDP). Although ABHDP is shown as the single stereoisomer
that binds to SmARG, the racemic mixture was utilized for the experiments described herein.
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restriction enzyme recognition sites)]. The PCR product was
subcloned into NdeI and XhoI sites of the pET-28a vector
(Novagen Inc.), yielding an N-terminal hexahistidine tag, a
thrombin cleavage site, and a linker (MGSSHHHHHHSSGL-
VPRGSHM). All DNA constructs were verified by DNA
sequencing at the Perelman School of Medicine of the
University of Pennsylvania.
SmARG was overexpressed in Escherichia coli BL21(DE3)
cells. Transformed cell cultures were grown in Lysogeny-Broth
(LB) medium supplemented with 50 μg/L kanamycin.
Expression was induced by 1 mM isopropyl β-D-1-thiogalacto-
pyranoside (IPTG) (Carbosynth) for 16 h at 20 °C when the
OD600 reached 0.6−0.7. Cells were harvested by centrifugation
at 6000g for 10 min. The cell pellet was resuspended in buffer A
[50 mM K2HPO4 (pH 8.0), 300 mM NaCl, 10% (v/v) glycerol,
and 1 mM TCEP]. Cells were lysed by sonication on ice using a
Sonifer 450 (Branson), and the cell lysate was clarified by
centrifugation at 26895g for 1 h. Proteins were isolated from
lysate by affinity chromatography with a Talon column
(Clontech Laboratories, Mountain View, CA). After being
washed with 10 column volumes of 20 mM imidazole in buffer
A, SmARG was eluted with a 200 mL gradient from 20 to 300
mM imidazole. Pooled fractions were concentrated and applied
to a Superdex 200 preparative grade 26/60 size exclusion
column (GE Healthcare) with buffer B [50 mM bicine (pH
8.5) and 100 μM MnCl2]. The estimated purity of SmARG was
>95% on the basis of sodium dodecyl sulfate−polyacrylamide
gel electrophoresis. Although the N-terminal hexahistidine tag
and linker segment contained a thrombin cleavage site, the
recombinant enzyme was not treated with thrombin and hence
contained a full-length N-terminus. The enzyme was
concentrated to 40 mg/mL, flash-frozen with liquid nitrogen,
and stored at −80 °C.
The C291A and C332A mutants of SmARG were prepared
by PCR mutagenesis with the following primers (underlined
bases indicate mutated codons): C291A, 5′-GAA GGT TTG
AGA ATA GCT GAA GAA GTT TC-3′ (sense) and 5′-GAA
ACT TCT TCA GCT ATT CTC AAA CCT TC-3′
(antisense); C332A, 5′-CAT ATT TTA AGA GCA GCT
TTA GGC CAT TGT CG-3′ (sense) and 5′-CGA CAA TGG
CCT AAA GCT GCT CTT AAA ATA TG-3′ (antisense).
Each mutant was purified as described above for the wild-type
enzyme.
Activity Assays. Arginase activity was assayed by a
colorimetric assay developed by Archibald with slight
modifications.36 Briefly, 0.5−50 mM L-arginine (pH 8.5) was
added to a solution of 50 mM 4-(2-hydroxyethyl)piperazine-1-
propanesulfonic acid (EPPS) (pH 8.5) and 100 μMMnCl2, and
the reaction was initiated by adding 1 μM SmARG in a total
volume of 200 μL at 21 °C. The reaction was terminated after 1
min using 30 μL of a 3:1 (v/v) concentrated acid/dye solution
{H2SO4/H3PO4/H2O [1:3:1 (v/v/v)] mixture with 245 mM α-
isonitrosopropiophenone in ethanol}. Samples were heated to
90 °C for 1 h in a thermocycler to ensure complete reaction of
urea with the dye. To quantify urea formation, the absorbance
of each sample was assessed at a λ of 550 nm using a Tecan
Infinite M1000 Pro Microplate Reader. Kinetic parameters
were determined with Graphpad Prism (2008). The Ki values
for ABH and NOHA were calculated using the modified
Michaelis−Menten equation for competitive inhibition. All
measurements were performed in triplicate.
Isothermal Titration Calorimetry (ITC). A MicroCal
iTC200 calorimeter (GE Healthcare) was used to measure the
dissociation constants of SmARG−inhibitor complexes using
previously reported procedures.16,31 Briefly, SmARG was
exhaustively dialyzed against 50 mM Bicine (pH 8.5), 100
μMMnCl2, and 1.0 mM TCEP [5% (v/v) DMSO was included
in the dialysis buffer when SmARG was titrated with ABHPE
and ABHDP]. The inhibitor (ABH, 0.547 mM; NOHA, 1.097
mM; nor-NOHA, 0.443 mM; ABHPE, 0.410 mM; ABHDP,
0.436 mM) was dissolved in dialysis buffer. The inhibitor was
titrated into the sample cell (0.2 mL) overfilled with SmARG
(typically 20−40 μM) with sequential injections. An initial 0.2
μL injection was not used in the data analysis. Data analysis was
performed using Origin version 7.0. For SmARG complexes
with nor-NOHA, ABH, ABHPE, and ABHDP, data were best fit
assuming a single binding site. For the SmARG−NOHA
complex, data were best fit with the equation describing two
sets of independent sites, i.e., a model in which binding to one
site (association constant K1) has a higher affinity than binding
to the second site (association constant K2):
= Δ
+
+ Δ
+
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where Q is the heat evolved during the course of the reaction,
[E]t is the total enzyme concentration, V is the cell volume, n1
is the number of inhibitor equivalents required to saturate the
first binding site, n2 is the number of equivalents to saturate the
second site, ΔH1 and ΔH2 are the enthalpies per mole of ligand
of binding to the first and second sites, respectively, and [L] is
the inhibitor concentration. Note that dissociation constants
Kd1 = 1/K1 and Kd2 = 1/K2.
Crystallography. Unliganded SmARG crystals were
prepared by the sitting drop vapor diffusion method at 4 °C.
Typically, a 4 μL drop of a protein solution [10 mg/mL
SmARG, 50 mM bicine (pH 8.5), and 100 μM MnCl2] was
mixed with a 4 μL drop of a precipitant solution [12% (w/v)
PEG 20000 and 0.1 M imidazole (pH 7.0)] and equilibrated
against a 500 μL reservoir of a precipitant solution. Cubic
crystals first appeared after 2 days and grew to maximal size in 3
days. To obtain crystals of the SmARG−L-ornithine, SmARG−
L-valine, and SmARG−L-lysine complexes, unliganded SmARG
crystals were soaked with each ligand (50 mM) in a 20 μL drop
of a soaking solution [14% PEG 20000 and 0.1 M imidazole
(pH 7.0)] equilibrated against a 500 μL reservoir of a soaking
solution for 24 h. To cocrystallize SmARG with the higher-
affinity arginase inhibitors ABH, BEC, NOHA, and nor-NOHA,
as well as the α,α-disubstituted amino acid inhibitors ABHPE
and ABHDP, SmARG was incubated with each inhibitor (10
mM) on ice for 1 h before the crystallization experiment.
Typically, a 1 μL drop of protein solution (9 mg/mL SmARG,
45 mM bicine, 90 μM MnCl2, and 10 mM inhibitor) was added
to a 1 μL drop of a precipitant solution [4% (v/v) Tacsimate
(pH 7.0) and 12% (w/v) PEG 3350 for SmARG−ABH and
SmARG−BEC complexes; 0.2 M potassium sodium tartrate
tetrahydrate, 0.1 M Bis-Tris (pH 6.5), and 10% (w/v) PEG
10000 for the SmARG−NOHA complex; 0.2 M L-proline, 0.1
M HEPES (pH 7.5), and 10% (w/v) PEG 3350 for the
SmARG−norNOHA complex; 0.1 M HEPES (pH 7.4) and
12% (w/v) PEG 3350 for the SmARG−ABHPE complex; and
0.15 M CsCl and 13% (w/v) PEG 3350 for the SmARG−
ABHDP complex] and equilibrated against a 100 μL reservoir of
a precipitant solution. Cubic crystals appeared overnight and
grew to maximal size in 3 days. All crystals were flash-cooled in
liquid nitrogen after being transferred to a cryoprotectant
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solution consisting of mother liquor supplemented with 15−
20% (v/v) glycerol.
X-ray diffraction data were collected on beamline X29 at the
National Synchrotron Light Source (NSLS, Brookhaven
National Laboratory, Upton, NY). Diffraction data were
integrated and scaled with HKL2000.37 Data collection and
reduction statistics are listed in Table 1. All crystals belonged to
space group P213 with four molecules in the asymmetric unit,
each belonging to a separate SmARG trimer in the unit cell.
The structure of unliganded SmARG was determined by
molecular replacement using PHASER38 as implemented in the
CCP4 suite of programs39 with the atomic coordinates of
unliganded human arginase I (PDB entry 2ZAV)40 utilized as a
search probe for rotation and translation function calculations.
Iterative cycles of refinement and model building were
performed using PHENIX and COOT, respectively.41,42 The
structures of SmARG−inhibitor complexes were determined
thereafter by molecular replacement using the atomic
coordinates of unliganded SmARG as a search probe. Solvent
molecules and inhibitors were added in the final stages of
refinement for each structure. The quality of each final model
was verified with PROCHECK, and the secondary structure
was defined with DSSP.43,44 Disordered segments excluded
from the final models include the N-terminal hexahistidine tag
and its linker segment, residues M1−P17, surface loop K111−
S119, and T362−Q364 at the C-terminus. Refinement statistics
are listed in Table 1. Protein structure figures were prepared
with PyMol (http://www.pymol.org) and PhotoshopCS.
SmARG Transcription Profile. Data from the 37632-
element S. mansoni long-oligonucleotide DNA microarray
studies of Fitzpatrick and colleagues45 were interrogated to
find the expression profile of SmARG across 14 different life
cycle stages. Raw and normalized fluorescence intensity values
are available via Array Express under experimental accession
number E-MEXP-2094.
Helminth Fluorescence Bioassay. Mechanically trans-
formed S. mansoni schistosomula were treated with the arginase
inhibitors ABH (Enzo Life Sciences), NOHA (Sigma), and
nor-NOHA (Enzo Life Sciences) at a final concentration of 100
μM and incubated for 24 h at 37 °C in a humidified
environment containing 5% CO2. The viability of S. mansoni
schistosomula subsequent to treatment was determined using
the helminth fluorescence bioassay as previously described.46
All assays were performed in duplicate.
■ RESULTS
SmARG Transcription Profile. The transcription profile of
SmARG across 14 different S. mansoni life cycle stages (Figure
2) confirms previously published semiquantitative reverse
transcription PCR data showing that SmARG is maximally
expressed in all life stages that interact with the definitive
mammalian host but minimally expressed in life stages that
interact with the intermediate snail host.45 Thus, the
upregulation of SmARG is specific to human infection by S.
mansoni. If SmARG plays an important role during human
infection, it could serve as a new target for the treatment of
schistosomal infections.
Activity Assays and ITC Measurements. Our measure-
ments show that wild-type SmARG exhibits a turnover number
(kcat) of 330 ± 60 s
−1 and a KM value of 12 ± 5 mM at pH 8.5
using Archibald’s colorimetric assay36 to quantify urea
production in steady-state kinetic assays (Table 2). These
values are in reasonable agreement with previously reported
values of 537 s−1 and 17 mM, respectively, for a slightly
different SmARG construct at pH 9.7 containing the remnant
of an N-terminal glutathione S-transferase fusion tag15 instead
of the hexahistidine tag and linker utilized herein. These values
are also comparable to those measured for human arginase I,
although the KM values of SmARG are slightly larger (4−6-
fold) than the KM value reported for the human enzyme (Table
2).
Steady-state kinetic analysis yields an inhibition constant (Ki)
of 1.8 ± 0.6 μM for the SmARG−ABH complex, which is
consistent with the ITC measurement of 1.3 ± 0.2 μM for the
dissociation constant (Kd) of this complex (Figure S1 of the
Supporting Information). Interestingly, ITC measurements
indicate 260-fold tighter binding of ABH to human arginase
I, but the inhibitory potencies of ABH against SmARG and
human arginase I are comparable (Table 2). The origin of the
difference between Ki and Kd values is unknown.
ITC measurements indicate that Kd = 0.36 ± 0.08 μM for the
SmARG−nor-NOHA complex (Figure S1 of the Supporting
Information). The binding of NOHA is slightly more complex,
and ITC data are best fit by a model in which the binding
affinity for the first site is higher (Kd = 0.33 ± 0.09 μM) than
the binding affinity for the second site (Kd = 13 ± 4 μM). The
location of the weaker binding site is unknown, because only
the higher-affinity binding site is occupied in the crystal
structure of the SmARG−NOHA complex (vide inf ra). Taken
together, these data suggest that the N-hydroxyguanidinium
moiety of nor-NOHA is ∼4-fold more effective as an inhibitor
functional group targeting metal ion coordination than the
tetrahedral boronate anion of ABH in binding to SmARG. This
contrasts with human arginase I, which is preferentially
inhibited (at least 10-fold) by ABH compared with nor-
NOHA.16,47 Possibly, these selectivity differences (summarized
in Table 2) could be exploited in developing inhibitors that
preferentially block the parasitic enzyme.
Finally, ITC measurements indicate Kd values of 0.26 ± 0.02
and 0.54 ± 0.08 μM for SmARG−ABHPE and −ABHDP
complexes, respectively (Figure S1 of the Supporting
Information). Notably, the additional α-substituent of these
Figure 2. Expression profile of SmARG across 14 different life cycle
stages of S. mansoni shown following interrogation of the 37632-
element DNA microarray. Raw and normalized fluorescence intensity
values are available via Array Express under experimental accession
number E-MEXP-2094. Histograms represent the normalized mean
fluorescence intensity ± the standard deviation of the mean.
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α,α-disubstituted amino acid inhibitors provides 2−5-fold
enhancement of the affinity compared with that of the parent
SmARG−ABH complex.
Structure of Unliganded SmARG. The overall fold of the
SmARG monomer is generally similar to that of unliganded
human aginase I (PDB entry 2ZAV)40 with an rmsd of 1.1 Å
for 271 Cα atoms, which is consistent with the modest amino
acid sequence identity of 42% between SmARG and human
arginase I. SmARG oligomerizes to form a homotrimer (Figure
3a) with a total buried surface area of 10980 Å2 (31% of the
total solvent-accessible surface area) as determined by PISA.48
As indicated by the sequence alignment with human arginase I,
SmARG contains a 20-residue extension at the N-terminus and
a 13-residue extension at the C-terminus, and a 12-residue
insertion in the loop connecting α-helix B and β-strand 3.15
The N-terminal extension (17 residues with the hexahistidine
tag and its linker segment) and the inserted loop lack clearly
defined electron density and are presumed to be disordered.
Most of the C-terminal extension is fully ordered and contains
two additional short α-helices previously unobserved in the
crystal structures of arginases from other species. The S-shaped
C-terminus is suggested to be important for oligomerization
and mediates 54% of the intermonomer contact surface area in
rat arginase I,49 although mutagenesis studies suggest that
mutations in the C-terminus destabilize but do not necessarily
prevent the trimerization of rat arginase I or human arginase
I.50−52 The unusually long C-terminal tail of SmARG is
similarly responsible for the majority of subunit−subunit
interactions; the 13-residue extension alone contributes
∼3900 Å2 of total buried surface area (36% of the total buried
surface area) to trimer assembly.
The structure of the binuclear manganese cluster (Figure 3b)
is essentially identical to that observed in unliganded arginases
from other species, such as human arginase I (Figure 3c). Each
Mn2+ ion is coordinated in octahedral or distorted octahedral
fashion by two nonprotein ligands and conserved metal binding
residues. The metal-bridging nonprotein ligand is expected to
be a hydroxide ion in the catalytically active state, and the
Mn2+A-bound nonprotein ligand is interpreted as a water
molecule. This is similar to the identification of nonprotein
metal ligands in unliganded human arginase I,40 Bacillus
caldovelox arginase,53 and Leishmania mexicana arginase.54
Most other inner active site residues are conserved in
SmARG, except that T135 in human arginase I is conserved
as S165 in SmARG (Figure 3c).
Although Fitzpatrick and colleagues suggest that the SmARG
activity is dependent on a disulfide bond formed between C291
and C332 on the basis of homology modeling,15 no disulfide
bond is observed in the crystal structure, even though the Sγ
atoms of C291 and C332 are only 3.5 Å apart and no reducing
agents were included in crystallization buffers (Figure S2a of
the Supporting Information). It is clear, however, that SmARG
activity is severely attenuated in the presence of reducing
reagents such as TCEP (Figure S2b of the Supporting
Information). Our modeling studies indicate that side chain
torsion angle χ2 of C291 could be rotated by 54° to allow the
formation of a disulfide bond with C332. The geometry of this
disulfide linkage would be classified as -RHStaple, which
corresponds to the geometry of allosteric disulfide linkages that
regulate protein function by triggering reversible changes in
protein tertiary structure.55 Even so, the side chain con-
formations of C291 and C332 would be unfavorable if this
disulfide bond were formed.
To probe the functional importance of a possible disulfide
linkage between C291 and C332, we prepared the C291A and
C332A mutants of SmARG and measured their steady-state
kinetics (Table 2). These mutants are chemically incapable of
forming a covalent linkage between residues 291 and 332;
notably, however, these mutants exhibit significant residual
activity (∼30% based on kcat). Catalytic efficiencies (kcat/KM)
are compromised 25-fold for C291A SmARG and only 9-fold
for C332A SmARG. Thus, formation of a disulfide linkage
between C291 and C332 is not required for catalysis but might
be required for maximal catalytic function.
Structures of Complexes of SmARG with Simple
Amino Acids. The overall structure of SmARG in each
complex with the amino acid inhibitors L-ornithine, L-valine,
and L-lysine is essentially identical to the structure of
unliganded SmARG; the rmsds between liganded and
unliganded structures are 0.17 Å for 322 Cα atoms in the
SmARG−L-ornithine complex, 0.17 Å for 319 Cα atoms in the
SmARG−L-valine complex, and 0.30 Å for 316 Cα atoms in the
SmARG−L-lysine complex. As is evident in Figure 4, the
molecular recognition of the catalytic product L-ornithine, the
product analogue L-lysine, and the weak inhibitor L-valine is
dominated by three direct and four water-mediated hydrogen
bonds that selectively accommodate the α-amino and α-
carboxyl groups of an amino acid with L-stereochemistry. This
hydrogen bond network comprises the L-amino acid recog-
nition motif, as first observed in the rat arginase I−ABH
complex.56
Table 2. Enzyme Kinetics and Inhibitor Binding Affinities
KM (mM) kcat (s
−1) kcat/KM (M
−1 s−1)
Ki (ABH)
(μM)
Kd (ABH)
(μM)
Ki
(NOHA)
(μM)
Kd (NOHA)
(μM)
Kd
(nor-NOHA)
(μM)
Kd (ABHPE)
(μM)
Kd (ABHDP)
(μM)
wild-type
SmARGa
12 ± 5 330 ± 60 (3.0 ± 0.9) × 104 1.8 ± 0.6 1.3 ± 0.2 3.7 ± 0.8 0.33 ± 0.09,
13 ± 4
0.36 ± 0.08 0.26 ± 0.02 0.54 ± 0.08
C291A
SmARGa
90 ± 10 110 ± 10 (1.2 ± 0.3) × 103 nd nd nd nd nd nd nd
C332A
SmARGa
32 ± 9 100 ± 20 (3.3 ± 0.6) × 103 nd nd nd nd nd nd nd
SmARGb 17 537 3.2 × 104 nd nd nd nd nd nd nd
human
arginase I
3 ± 1c 340 ± 160c (11 ± 2) × 104c 3.5d 0.005e nd 3.6f 0.517g nd nd
aThis study; determined by an enzyme assay at pH 8.5. bFrom ref 15; determined by an enzyme assay at pH 9.7. cFrom ref 63; determined by an
enzyme assay at pH 8.5. dFrom ref 64; determined by an enzyme assay at pH 9.5. eFrom ref 16; Kd determined at pH 8.5 by isothermal titration
calorimetry. fFrom ref 47; Kd determined at pH 8.5 by surface plasmon resonance.
gFrom ref 47; Kd determined at pH 8.5 by surface plasmon
resonance; however, isothermal titration calorimetry yielded a Kd of ∼50 nM.
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Structures of Complexes of SmARG with N-Hydrox-
yguanidinium Inhibitors. The overall structure of the
SmARG−NOHA complex is essentially identical to that of
unliganded SmARG, with an rmsd of 0.23 Å for 316 Cα atoms.
The α-amino and α-carboxyl groups of NOHA hydrogen bond
with the L-amino acid recognition motif, and the Nη-OH group
interacts with the binuclear manganese cluster (Figure 5a).
Intriguingly, however, the electron density map indicates that
the N-hydroxyguanidinium group binds with two alternative
conformations. In the major conformation (refined with 75%
occupancy), the Nη-OH group of NOHA displaces the metal-
bridging hydroxide ion and symmetrically bridges the binuclear
manganese cluster with an average Mn2+···O coordination
distance of 1.8 Å, and the Mn2+A−Mn2+B separation increases
from 3.1 to 3.3 Å. The η-NH2 group of NOHA is oriented
toward Mn2+A (but does not coordinate) and donates a
hydrogen bond to E307. This conformation is similar to that
observed in the 2.9 Å resolution crystal structure of the rat
arginase I−NOHA complex (PDB entry 1HQF).57
In the minor conformation (refined with 25% occupancy),
the Nη-OH group of NOHA displaces the Mn2+A-bound water
molecule with an average Mn2+A···O coordination distance of
2.0 Å. The metal-bridging hydroxide ion must also be displaced
to accommodate NOHA binding in this conformation, so both
Mn2+A and Mn
2+
B exhibit square bipyramidal coordination
geometry. Two hydrogen bonds are observed between SmARG
and NOHA in its minor conformation: the Nη-H group of
NOHA donates a hydrogen bond to D158, and the η-NH2
group donates a hydrogen bond to T276. These interactions
are similar to those observed in the 2.04 Å resolution crystal
Figure 3. (a) Structure of the SmARG homotrimer. α-Helices are colored salmon, β-strands blue, and Mn2+ ions purple. The elongated S-shaped C-
terminus is colored magenta, and the disordered K111−S119 loop appears as a yellow dotted line. (b) Simulated annealing omit map contoured at
4.0σ of the metal-bound solvent molecules in unliganded SmARG. Atoms are color-coded as follows: white for C, blue for N, red for O, purple
spheres for Mn2+ ions, and red spheres for solvent molecules. Metal coordination and hydrogen bond interactions are represented by red and green
dashed lines, respectively. (c) Superposition of unliganded SmARG (color-coded as in panel b, with black residue labels) and human arginase I (PDB
entry 2ZAV; yellow for C, blue for N, red for O, pink spheres for Mn2+ ions, and yellow spheres for solvent molecules with red residue labels).
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structure of the human arginase I−NOHA complex (PDB entry
3LP7) (Figure S3 of the Supporting Information).47
Finally, the overall structure of SmARG in its complex with
nor-NOHA is essentially identical to that of unliganded
SmARG, with an rmsd of 0.19 Å for 331 Cα atoms. The
amino acid moiety of nor-NOHA is accommodated by the L-
amino acid recognition motif, as observed for NOHA.
However, in contrast with the binding of NOHA, the N-
hydroxyguanidinium group of nor-NOHA binds with just a
single conformation in which the Nζ-OH group displaces the
metal-bridging hydroxide ion and bridges the binuclear
manganese cluster with average MnA
2+···O and MnB
2+···O
coordination distances of 1.9 and 2.2 Å, respectively (Figure
5b). The ζ-NH group of nor-NOHA donates a hydrogen bond
to D158, and the ζ-NH2 group is oriented toward Mn
2+
B (but
does not coordinate) and donates a hydrogen bond to T276.
Structures of Complexes of SmARG with Classical
Boronic Acid Inhibitors. The crystal structure of the
SmARG−ABH complex reveals that no significant conforma-
tional changes are triggered upon inhibitor binding, and the
rmsd is 0.15 Å for 318 Cα atoms in comparison with the
unliganded enzyme. The simulated annealing omit map in
Figure 6 reveals that the boronic acid group of ABH undergoes
nucleophilic attack, presumably by the metal-bridging hydrox-
ide ion of the native enzyme, to form the tetrahedral boronate
anion, which mimics the tetrahedral intermediate and its
flanking transition states in the arginase reaction.30 The α-
carboxylate group and α-amino group of ABH hydrogen bond
with the L-amino acid recognition motif, as first observed in the
Figure 4. Simulated annealing omit maps of amino acids bound in the active site of SmARG: (a) L-ornithine, contoured at 3.0σ; (b) L-valine,
contoured at 3.0σ; and (c) L-lysine, contoured at 5.5σ. Atoms are color-coded as follows: white (protein) or yellow (inhibitor) for C, blue for N, red
for O, green for B, purple spheres for Mn2+ ions, and red spheres for solvent molecules. Metal coordination and hydrogen bond interactions are
represented by red and green dashed lines, respectively. The α-amino and α-carboxyl groups of each amino acid make an array of direct and water-
mediated hydrogen bonds with conserved protein residues D213, E216, N160, S165, S167, N169, and H171. These residues comprise the L-amino
acid recognition motif.
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crystal structure of the rat arginase I−ABH complex.56 This
structure serves as a starting point for understanding structure−
activity relationships for α,α-disubstituted ABH derivatives
described below.
The crystal structure of the SmARG−BEC complex,
although determined at a lower resolution of 2.7 Å, similarly
reveals the binding of the tetrahedral boronate anion and an
array of hydrogen bonds with the α-amino acid moiety (Figure
S4 of the Supporting Information). No significant conforma-
tional changes are triggered upon inhibitor binding, and the
rmsd is 0.26 Å for 320 Cα atoms in comparison with the
unliganded enzyme. Although fewer water molecules are
observed in the active site because of the modest resolution,
the structure of the SmARG−BEC complex is similar to that
first observed in the rat arginase I−BEC complex.31
Structures of Complexes of SmARG with α,α-
Disubstituted Boronic Acid Inhibitors. The structure of
the SmARG−ABH complex reveals that the Cα-H group of
ABH can be substituted with an additional side chain capable of
making additional interactions on the protein surface. To
demonstrate the proof of concept, we have determined the
crystal structures of SmARG complexes with the novel α,α-
disubstituted amino acid inhibitors ABHPE and ABHDP (Figure
1b). The overall structures of SmARG complexed with ABHPE
Figure 5. (a) Simulated annealing omit map (contoured at 3.0σ) of the inhibitor NOHA that reveals that the hydroxyguanidinium group adopts two
alternate conformations. Atoms are color-coded as in Figure 4. Metal coordination and hydrogen bond interactions are represented by red and green
dashed lines, respectively. Note that residue D213 adopts two alternate conformations. (b) Simulated annealing omit map (contoured at 3.0σ) of the
inhibitor nor-NOHA. Atoms are color-coded as in Figure 4. Metal coordination and hydrogen bond interactions are represented by red and green
dashed lines, respectively.
Figure 6. Simulated annealing omit map (contoured at 3.0σ) of boronic acid inhibitor ABH. Atoms are color-coded as in Figure 4. Metal
coordination and hydrogen bond interactions are represented by red and green dashed lines, respectively.
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and ABHDP are essentially identical to the structure of
unliganded SmARG, with rmsds of 0.19 Å for 332 Cα atoms
and 0.17 Å for 330 Cα atoms, respectively. Although racemic
ABHDP was used in the crystallization experiment with
SmARG, the electron density map clearly shows that the
stereoisomer corresponding to L-ABH binds exclusively in the
active site. As shown in Figure 7, the boronic acid moiety of
each inhibitor undergoes nucleophilic attack by the metal-
bridging hydroxide ion to form a tetrahedral boronate anion, as
observed in the crystal structure of the parent SmARG−ABH
complex (Figure 6). However, in contrast with the SmARG−
ABH complex, the additional α-substituents of ABHPE and
ABHDP block the binding of water molecule W4; this water
molecule ordinarily mediates a hydrogen bond between the
inhibitor α-amino group and D213 (Figure 7c). Therefore, the
L-amino acid recognition motif in the active site of SmARG is
slightly compromised by the binding of α,α-disubstituted amino
acid inhibitors. Regardless, the additional α-substituents of both
ABHPE and ABHDP make additional interactions in the active
site of SmARG, which presumably accounts for the affinity of
these inhibitors being higher than that of ABH.
In each enzyme−inhibitor complex, the piperidine ring
exclusively adopts a chair conformation and its protonated
tertiary amino group donates a hydrogen bond to D213 (purple
dashed lines in panels a and b of Figure 7; average N···O
separations of 2.7 Å in the SmARG−ABHPE complex and 2.9 Å
in the SmARG−ABHDP complex). Additionally, the dichlor-
obenzyl group of ABHDP interacts with E58 from an adjacent
monomer (panels b and c of Figure 7). Incomplete electron
density for the dichlorobenzyl group of ABHDP and a higher
average temperature factor (∼55 Å2) compared with that of the
piperidine ring (∼30 Å2) suggest increased flexibility.
Structural comparison of the SmARG−ABHPE complex with
the 1.30 Å resolution crystal structure of the human arginase I−
ABHPE complex (PDB entry 4HWW)
34 reveals striking
differences in the conformation of the piperidine α-substituent
of ABHPE, even though the parent ABH scaffold retains the
same conformation in both structures (Figure 8a). Van Zandt
and colleagues note that the piperidine ring of ABHPE adopts
two alternate conformations in the human arginase I−ABHPE
complex: distorted boat (66%) and chair (33%).34 With the
piperidine ring of ABHPE shifted farther from D183 in the
human arginase I−ABHPE complex (D183 of human arginase I
corresponds to D213 of SmARG), it makes water-mediated
hydrogen bonds with D183 and D181 through water molecules
W1 and W4, instead of making a direct hydrogen bond as
observed in the SmARG−ABHPE complex. More importantly,
because of the conservation of water molecule W4, the L-amino
acid recognition motif is intact in the human arginase I−ABHPE
complex.
Figure 7. Simulated annealing omit maps of α,α-disubstituted amino acid inhibitors: (a) ABHPE, contoured at 5.0σ, and (b) ABHDP, contoured at
3.0σ. Atoms are color-coded as in Figure 4 (dark green for Cl). Metal coordination and hydrogen bond interactions are represented by red and green
dashed lines, respectively. Note that residue E58 from an adjacent monomer of the homotrimer adopts two alternate conformations (highlighted in
cyan). (c) Superposition of the SmARG−ABH complex (white for C and Mn2+), the SmARG−ABHPE complex (salmon for C and Mn2+), and the
SmARG−ABHDP complex (yellow for C and Mn2+).
Biochemistry Article
dx.doi.org/10.1021/bi5004519 | Biochemistry 2014, 53, 4671−46844680
Structural differences in the binding of an α,α-disubstituted
amino acid are also revealed in the comparison of the
SmARG−ABHDP complex with the complex between human
arginase II and (R)-2-amino-6-borono-2-[1-(4-chlorobenzyl)-
piperidin-4-yl]hexanoate (ABHDP1, which differs from ABHDP
by one chlorine atom on the pendant aromatic ring; PDB entry
4IXV)35 (Figure 8b). Here, too, the parent ABH structures
adopt similar conformations; however, significant conforma-
tional differences are observed for the additional α-substituents
of ABHDP and ABHDP1. The piperidine ring of ABHDP1 in the
human arginase II−ABHDP1 complex adopts a distorted boat
conformation, with the piperidine amino group forming a
water-mediated hydrogen bond with S155 (equivalent to T136
in human arginases I and II), instead of hydrogen bonding with
D213, as observed in the SmARG−ABHDP1 complex. Addi-
tionally, the chlorobenzyl ring of ABHDP1 does not interact with
the protein.
Active site comparisons reveal that A166 (equivalent to T136
in human arginase I and S155 in human arginase II) is another
nonconserved residue in SmARG (besides S165) that can
interact with α,α-disubstituted amino acid inhibitors (Figure 8).
Interestingly, the corresponding residue is similarly nonpolar in
two other parasitic arginases: P228 in Plasmodium falciparum
arginase58 and V149 in L. mexicana arginase.54 Differences in
polarity and size at this position between parasitic arginases and
human arginases may be a contributing factor to the alternative
binding modes of α,α-disubstituted amino acid inhibitors.
Coculture of Schistosomula with ABH, NOHA, and
nor-NOHA. The helminth fluorescence bioassay was utilized to
assess the effect of SmARG inhibitors on schistosomula viability
during continuous in vitro cocultivation. Despite the ability of
these inhibitors to effectively bind to SmARG, no significant
difference in parasite viability or morphology was observed
during treatment with 100 μM ABH, NOHA, or nor-NOHA
for 24 h (Figure S5 of the Supporting Information) or 72 h
(data not shown). If the uptake of amino acid inhibitors is
facile, this result suggests that any effect of SmARG inhibitors
on parasite viability would require the presence of the human
host.
■ DISCUSSION
Biological Insight into SmARG as a Drug Target for
Schistosomiasis. Using a 37632-element long-oligonucleotide
DNA microarray, new S. mansoni anthelmintic drug targets
were revealed through parasite life cyle transcriptomic
profiling.45 Here, we show that one putative drug target,
SmARG,15 is maximally expressed in all life stages that interact
with the definitive mammalian host but minimally expressed in
life stages that interact with the intermediate snail host (Figure
2). These data confirm previously published semiquantitative
reverse transcription PCR data and indicate that the
upregulation of SmARG is specific to human infection by S.
mansoni. Curiously, however, SmARG is not secreted by
cercariae or schistosomula,15 so the influence of S. mansoni
infection on L-arginine concentrations in infected human tissues
presumably arises from the facile transport of L-arginine into
the parasite. The resultant depletion of host L-arginine pools
allows immune evasion, because depressed L-arginine concen-
trations can result in lower NO concentrations produced by
classically activated macrophages with known anti-schistoso-
mula function.59
In principle, then, the inhibition of SmARG might possibly
render the parasite more susceptible to host immunity during
infection. Consistent with this hypothesis, the classical arginase
inhibitors ABH, NOHA, and nor-NOHA do not affect parasite
viability in the absence of the host (Figure S5 of the Supporting
Figure 8. (a) Superposition of the SmARG−ABHPE complex [white (protein) or yellow (inhibitor) for C] with the human arginase I−ABHPE
complex (cyan for C; PDB entry 4HWW). (b) Superposition of the SmARG−ABHDP complex [white (protein) or yellow (inhibitor) for C] with the
human arginase II−ABHDP1 complex (cyan for C; PDB entry 4IXV). Selected hydrogen bonds are shown as purple dashed lines (SmARG) or black
dashed lines (human arginases). Solvent molecules are shown as small red spheres; Mn2+ ions are shown as purple and orange spheres in SmARG
and human arginases, respectively. Black residue labels correspond to SmARG, and red labels correspond to the human arginases.
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Information). The host immune response in vivo is presumably
required for the maximal anthelmintic effect of an arginase
inhibitor, as is the case for praziquantel.60
Inhibitor Design Strategy for SmARG. Although the
affinities of the classical arginase inhibitors ABH, NOHA, and
nor-NOHA are in the low micromolar range (Table 2), it is
somewhat surprising that these affinities fall short of the
nanomolar binding affinities reported for complexes with
human arginase I.16,47 The structural basis of the weaker
affinity is not clear on the basis of analysis of the crystal
structures, because each inhibitor makes essentially identical
metal coordination and hydrogen bond interactions in the
active site of SmARG compared with the active sites of
mammalian enzymes. It is clear, however, that the best
inhibitors of arginase from any species will bear side chains
capable of metal ion coordination. This accounts for the
generally weaker binding affinity of simple amino acids such as
L-valine, L-ornithine, and L-lysine, which do not interact directly
with the active site Mn2+ ions (Figure 4). Parenthetically, we
note that this feature facilitates release of the L-ornithine
product during catalysis.
The crystal structures of complexes of SmARG with ABH
and nor-NOHA reveal that the tetrahedral boronate anion and
the N-hydroxyguanidinium moiety serve as ideal functional
groups for metal ion coordination and active site hydrogen
bond interactions (Figures 5b and 6). The α-carboxylate and α-
amino group of each inhibitor also make an array of hydrogen
bond interactions with the L-amino acid recognition motif, and
these hydrogen bonds similarly make an important contribution
to enzyme−inhibitor affinity.61 Thus, in the quest to improve
SmARG−inhibitor affinity and selectivity, these conserved
features of enzyme−inhibitor recognition cannot be perturbed.
Inspection of the crystal structure of the SmARG−ABH
complex (Figure 6) revealed that the L-amino acid moiety is
oriented such that the Cα-H group could be substituted with a
longer side chain to generate an α,α-disubstituted amino acid
capable of maintaining active site interactions with its “L-side
chain” while engaging in new interactions on the protein
surface with its “D-side chain”. The binding of ABHPE and
ABHDP (Figure 7) with 2- and 5-fold higher affinity,
respectively (Figure S1 of the Supporting Information),
demonstrates the success of this strategy. Furthermore,
structural comparisons of the region that accommodates the
D-side chains of ABHPE and ABHDP indicate that this region,
designated the “D-cleft” or “T136 region”,62 differs between
SmARG and human arginase I. Specifically, the D-cleft of
SmARG is much more nonpolar and perhaps would better
accommodate hydrophobic D-side chains even longer than that
of ABHDP. Therefore, α,α-disubstituted amino acid inhibitors
based on the ABH or nor-NOHA scaffoldings with D-side
chains even more extensive than that of ABHDP could be
designed to further enhance binding affinity as well as
selectivity against SmARG. Future studies in this regard will
be reported in due course.
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